Bull, base and bear scenarios, opening on what this business has actually done — its realised growth rates and its own P/E range, not round numbers we chose.
Projections are part of Pro
Set the growth, margin and multiple yourself and watch the price land where your assumptions put it — for Tscan Therapeutics, Inc. and every other company we cover.
Try it first on NVDA, AAPL, META, NKE or CAKE, where it is open to everyone.
$0.16-1.6%Nov 13 close
The latest quarter (ended September 30, 2026) is from Tscan Therapeutics’s earnings press release of November 12, 2026. It will be replaced by the official quarterly report (10-Q) once Tscan Therapeutics files it.